Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Madrigal Pharmaceuticals, Inc. - Common Stock
(NQ:
MDGL
)
497.27
+497.22 (+965472.82%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Madrigal Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Where Will Madrigal Pharmaceuticals Be in 3 Years?
↗
June 15, 2024
The coast is clear for it to grow, for now.
Via
The Motley Fool
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
↗
June 12, 2024
On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90.
Via
Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
↗
June 11, 2024
Via
Benzinga
Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals
↗
June 10, 2024
Success isn't guaranteed, but both companies could become big winners.
Via
The Motley Fool
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
↗
June 05, 2024
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment....
Via
Benzinga
Is Madrigal Pharmaceuticals Stock a Buy?
↗
May 21, 2024
It's not the most prominent biotech, but it has an important claim to fame.
Via
The Motley Fool
2 Under-the-Radar Growth Stocks to Consider
↗
April 10, 2024
Don't ignore these innovative companies.
Via
The Motley Fool
1 No-Brainer Growth Stock to Buy Now
↗
April 03, 2024
This liver-disease specialist might be significantly undervalued.
Via
The Motley Fool
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
↗
June 05, 2024
Researchers published results Wednesday showing Lilly's weight-loss drug could work in a liver disease.
Via
Investor's Business Daily
DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
June 05, 2024
Via
Benzinga
Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease Drug
↗
June 04, 2024
Viking Therapeutics stock falls despite seemingly positive test results for a drug that treats a serious liver disease.
Via
Investor's Business Daily
The Week Ahead: What's Next
↗
June 02, 2024
The core part of our portfolio is up 24% this year ... and we're about to add another stock. Plus, a riddle.
Via
Talk Markets
MDGL Stock Earnings: Madrigal Pharmaceuticals Misses EPS for Q1 2024
↗
May 07, 2024
MDGL stock results show that Madrigal Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock
↗
March 26, 2024
This biotech just got clearance to dive into a deep ocean of a market.
Via
The Motley Fool
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
May 07, 2024
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
May 03, 2024
Via
Benzinga
6 Stocks Positioned to Soar as Investors Focus on MASH
April 22, 2024
Investors are making a lot of money on obesity plays. Obesity is at epidemic proportions, so it's easy to see why obesity drugs including GLP-1 agonists have exploded in the marketplace. This class of...
Via
TheNewswire.com
7 Stocks Analysts Are Loving Right Now (And You Should Too): April 2024
↗
April 15, 2024
Analyst-backed stocks have a high correlation with future stock price growth. Here are seven stocks with a high number of recent upgrades.
Via
InvestorPlace
Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics
↗
April 05, 2024
These businesses should see good times ahead.
Via
The Motley Fool
The 3 Best Biotech Stocks to Buy in April 2024
↗
April 01, 2024
Biotech is one of the hottest sectors on the market, creating big opportunities for some of the best biotech stocks to buy in April.
Via
InvestorPlace
2 Top Biotech Buyout Candidates
↗
March 31, 2024
Investors who are adventurous, have a high-risk tolerance, and are home run hitters may opt for biotech stocks. Investors in this group may want to hone in on stocks that have the potential to be...
Via
Talk Markets
Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals
↗
March 29, 2024
Both stocks are pretty risky, but one of them more so than the other.
Via
The Motley Fool
Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval?
↗
March 29, 2024
Could it be just a matter of time before Madrigal Pharmaceuticals stock takes off?
Via
The Motley Fool
7 Stocks That Will Drive the Weight Loss Drugs Market
March 28, 2024
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.
Via
MarketBeat
This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy?
↗
March 22, 2024
The mid-cap biotech has succeeded where many others failed.
Via
The Motley Fool
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
↗
March 19, 2024
Madrigal has one key advantage over its two huge potential future rivals.
Via
The Motley Fool
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
↗
March 18, 2024
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas.
Via
InvestorPlace
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
↗
March 18, 2024
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.
Via
Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
↗
March 18, 2024
Via
Benzinga
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
↗
March 17, 2024
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
